Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

2019-12-07 00:56:44 | BioPortfolio


Patients with type 2 diabetes (T2D) suffer from an excess risk of adverse cardiovascular events. Recently, two classes of glucose lowering agents, namely SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA), have proved superior to placebo in protecting T2D patients from cardiovascular events in dedicated trials. Patient populations in such trials were mainly composed of T2D individuals with established cardiovascular disease (CVD) or at very high risk for CVD. In addition, no clinical trial has so far compared cardiovascular outcomes of T2D associated with SGLT2i versus GLP-1RA. In addition, whether different results would incur in patients at lower CVD risk is unclear. On this basis, we designed this retrospective real-world study to compare cardiovascular outcomes of patients newly treated with SGLT2i versus GLP-1RA in routine clinical practice

Study Design


Type 2 Diabetes


SGLT2 inhibitor, GLP-1 receptor agonist


Division of Metabolic Diseases, University Hospital of Padova




University of Padova

Results (where available)

View Results


Published on BioPortfolio: 2019-12-07T00:56:44-0500

Clinical Trials [6402 Associated Clinical Trials listed on BioPortfolio]

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

A. Four groups of patients with type 2 diabetes mellitus with high cardiovascular risk will be studied before and after 3 months of treatment: - 40 patients treated with a combination ...

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

1. Objectives 1. Which organ and how does SGLT2 inhibitor alter insulin sensitivity? 2. How does SGLT2 inhibitor increase glucagon levels and hepatic glucose production?

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin

The change of glycemic variation and insulin dose after adding SGLT2 inhibitor in type 2 diabetic patients treated with basal insulin was observed in a single center.

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

This is a proposal for a retrospective observational study of the safety of metformin use in patients with chronic kidney disease, compared to other commonly used diabetes drugs. It will b...

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

The primary aim of this observational study is to describe the effects of glucagon-like peptide-1 (GLP-1) receptor agonists and Sodium-Glucose Co-transporter 2 inhibitors ( SGLT-2 inhibito...

PubMed Articles [17579 Associated PubMed Articles listed on BioPortfolio]

An update on efficacy and safety of SGLT2 inhibitors in Asians and non-Asians.

Recent topics about SGLT2 inhibitor mainly focus on clinical studies, briefly mentioning its efficacy and safety in Asian and non-Asian type 2 diabetes patients. Sodium-glucose cotransporter 2 (SGLT2)...

Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes.

The risks of hypoglycemia, dehydration and kidney injury may theoretically be aggravated by people with type 2 diabetes treated with Insulin and SGLT2 inhibitors during Ramadan. Data on safety and eff...

Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.

Maintaining glycemic control limits costly health risks in patients with type 2 diabetes (T2D), but accomplishing this may require individualized strategies. Generic medications (eg, sulfonylureas [SU...

SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced ris...

Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes.

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new kind of hypoglycemic drugs that improve glucose homeostasis by inhibiting renal glucose reabsorption. Recent studies have shown that SGLT2 i...

Medical and Biotech [MESH] Definitions

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

A receptor that is specific for IGF-II and mannose-6-phosphate. The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF TYPE 1) and does not have a tyrosine kinase domain.

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.

More From BioPortfolio on "Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists"

Quick Search

Relevant Topic

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Searches Linking to this Trial